Table 2.
Characteristics of participants, symptomatic events, and testing results included in analysis.
| Any virus & S. pneumoniae (N = 157) | S. pneumoniae only (N = 189) | Total (N = 346) | |
|---|---|---|---|
| Baseline enrollment swab, N (%) | 50 (31.2%) | 108 (57.1%) | 158 (45.7%) |
| SARS-CoV-2 household contact, N (%) | 19 (12.1%) | 35 (18.5%) | 54 (15.6%) |
| Symptomatic, N (%) | |||
| Yesa | 74 (47.1%) | 37 (19.6%) | 111 (32.1%) |
| Days since symptom onset, median (IQRb) | 3.0 (2.0, 4.0) | 3.0 (1.5, 3.0) | 3.0 (2.0, 4.0) |
| Influenza-like illness (ILI)c,d | 33 (44.6%) | 16 (43.2%) | 49 (44.1%) |
| Difficulty breathingc | 11 (14.9%) | 3 (8.1%) | 14 (12.6%) |
| Chills or sweatsc | 22 (29.7%) | 9 (24.3%) | 31 (27.9%) |
| Coughc | 59 (79.7%) | 21 (56.8%) | 80 (72.1%) |
| Ear painc | 2 (2.7%) | 6 (16.2%) | 8 (7.2%) |
| Feeling more tired than usualc | 45 (60.8%) | 24 (64.9%) | 69 (62.2%) |
| Fever/feeling feverishc | 40 (54.1%) | 21 (56.8%) | 61 (55.0%) |
| Headachec | 19 (25.7%) | 15 (40.5%) | 34 (30.6%) |
| Muscle and/or body achesc | 16 (21.6%) | 7 (18.9%) | 23 (20.7%) |
| Runny nosec | 69 (93.2%) | 19 (51.4%) | 88 (79.3%) |
| Sore throatc | 28 (37.8%) | 15 (40.5%) | 43 (38.7%) |
| Absent from work or schoolc | 32 (43.2%) | 18 (48.6%) | 50 (45.0%) |
| Sought medical carec,e | 12 (16.2%) | 9 (24.3%) | 21 (18.9%) |
| Unknownf | 83 (52.9%) | 152 (80.4%) | 235 (67.9%) |
| Received current season influenza vaccine at time of testingg, N (%) | |||
| Yes | 116 (73.9%) | 134 (70.9%) | 250 (72.3%) |
| No | 24 (15.3%) | 43 (22.8%) | 67 (19.4%) |
| Unknown | 13 (8.3%) | 9 (4.8%) | 22 (6.4%) |
| Ineligibleh | 4 (2.5%) | 3 (1.6%) | 7 (2.0%) |
| S. pneumoniae Crt, median (IQRb) | 17.3 (14.0, 24.3) | 23.5 (18.8, 25.9) | 21.1 (15.8, 25.7) |
| Number of viruses detected, median (range) | 1 (1–4) | NA | NA |
| Swab typei, N (%) | |||
| Mid-turbinate | 118 (75.2%) | 124 (65.6%) | 242 (69.9%) |
| Anterior nasal | 39 (24.8%) | 65 (34.4%) | 104 (30.1%) |
Individuals considered to be symptomatic if they reported any of the following at either sample collection or on the one-week follow-up questionnaire: difficulty breathing, chills, sweats, cough, ear pain, fatigue, fever, headache, muscle and/or body aches, runny nose, or sore throat.
Interquartile range.
Proportions for specific symptoms, absence from work or school, and sought medical care are among those reporting any symptoms.
ILI includes fever with cough and/or sore throat.
Sought medical care unknown for one testing event.
Swabs with unknown symptom status include baseline enrollment swabs and swabs from household contacts after SARS-CoV-2 was detected in a household member (in the second year of the study only).
At the time of testing, had received 2019–2020 influenza vaccine for swabs collected between November 2019–July 2020 and 2020–2021 influenza vaccine for swabs collected between August 2020–June 2021.
Aged <6 months at the time of testing.
Mid-turbinate swabs used from November 19, 2019–July 22, 2020 and anterior nasal swabs used from July 22, 2020–June 18, 2021.